Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 6,620 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 6,620 shares of the business's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $54.84, for a total value of $363,040.80. Following the sale, the chief executive officer now owns 549,867 shares of the company's stock, valued at $30,154,706.28. The trade was a 1.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Andrew Cheng also recently made the following trade(s):

• On Tuesday, June 10th, Andrew Cheng sold 37,837 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.05, for a total transaction of $2,045,089.85.
• On Monday, May 12th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.48, for a total transaction of $1,244,400.00.
• On Thursday, April 10th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $35.23, for a total transaction of $1,056,900.00.

Akero Therapeutics Stock Down 0.3%

Shares of Akero Therapeutics stock traded down $0.17 during trading hours on Monday, hitting $54.03. 1,271,985 shares of the company's stock traded hands, compared to its average volume of 1,014,119. Akero Therapeutics, Inc. has a twelve month low of $21.02 and a twelve month high of $58.40. The company has a market cap of $4.31 billion, a PE ratio of -27.71 and a beta of -0.16. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. The stock has a 50 day simple moving average of $45.88 and a 200-day simple moving average of $41.25.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. Equities research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AKRO has been the subject of several recent research reports. Citigroup lowered their price target on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Bank of America increased their target price on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, HC Wainwright boosted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $82.50.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. RTW Investments LP grew its position in shares of Akero Therapeutics by 15.9% in the 4th quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock worth $190,840,000 after acquiring an additional 940,388 shares in the last quarter. Deep Track Capital LP lifted its stake in Akero Therapeutics by 116.0% during the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after purchasing an additional 800,216 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in Akero Therapeutics during the fourth quarter worth $18,059,000. SG Americas Securities LLC boosted its holdings in Akero Therapeutics by 93.3% in the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock worth $46,786,000 after purchasing an additional 557,794 shares during the period. Finally, Lord Abbett & CO. LLC bought a new stake in Akero Therapeutics during the first quarter valued at $21,333,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.